PharmaShots | Incisive News in 3 Shots

Subscribe Now

Tyvaso DPI

MannKind and United Therapeutics Reports the US FDA's Acceptance of NDA for Priority Review of Tyvaso DPI to Treat PAH and PH-ILD

MannKind and United Therapeutics Reports the US FDA's Acceptance of NDA for Priority Review of Tyvaso DPI to Treat PAH and PH-ILD

June 17, 2021

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us